<DOC>
	<DOCNO>NCT02425098</DOCNO>
	<brief_summary>The purpose study ass post-vaccination neutralize antibody response dengue serotype treatment arm .</brief_summary>
	<brief_title>Safety Immunogenicity With Two Different Serotype 2 Potencies Tetravalent Dengue Vaccine ( TDV ) Adults Singapore</brief_title>
	<detailed_description>The vaccine test study Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) . TDV test protect people dengue fever . This study look safety amount antibody dengue fever form people administer high-dose TDV ( HD-TDV ) compare TDV . The study enroll approximately 400 patient . Before assigned treatment group participant screen previous exposure dengue virus . Dengue naïve previously expose participant randomly assign ( chance ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - HD-TDV 0.5 mL subcutaneous injection - TDV 0.5 mL subcutaneous injection All participant receive single injection Day 1 . Participants ask record symptom may relate vaccine injection site diary card 28 day vaccination . This multi-center trial conduct Singapore . The overall time participate study 12 month . Participants make multiple visit clinic , include final visit 1 year receive dose TDV .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Participant sign date write informed consent form applicable , required privacy authorization prior initiation trial procedure , nature trial explain accord local regulatory requirement . 2 . Is age 21 45 year age , inclusive . 3 . Is good health time entry trial determine medical history , physical examination ( include vital sign ) clinical judgment Investigator . 4 . Can comply trial procedure available duration followup . 5 . Has selfdeclared never vaccinate Yellow Fever Japanese Encephalitis Virus . 1 . Has febrile illness ( temperature ≥38°C ≥100.4°F ) moderate severe acute illness infection time enrollment . 2 . Has history illness , opinion Investigator , might interfere result trial pose additional risk participant due participation trial , include limited : 1 . Known hypersensitivity allergy vaccine component . 2 . Female participant pregnant breastfeeding . 3 . Individuals serious chronic progressive disease accord judgment Investigator ( e.g . neoplasm , insulindependent diabetes , cardiac , renal hepatic disease , neurologic seizure disorder GuillainBarré syndrome ) . 4 . Known suspected impairment/alteration immune function , include : . Chronic use oral steroid ( equivalent 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 week ) within 60 day prior Day 1 ( Month 0 ) ( use inhale , intranasal , topical corticosteroid allow ) . ii . Receipt parenteral steroid ( equivalent 20 mg/day prednisone ≥12 weeks/≥ 2 mg/kg body weight/day prednisone ≥2 week ) within 60 day prior Day 1 ( Month 0 ) . iii . Administration immunoglobulins and/or blood product within 3 month prior Day 1 ( Month 0 ) plan administration trial . iv . Receipt immunostimulants within 60 day prior Day 1 ( Month 0 ) . v. Immunosuppressive therapy anticancer chemotherapy radiation therapy within 6 month prior Day 1 ( Month 0 ) . vi . Human immunodeficiency virus ( HIV ) infection HIVrelated disease . vii . Hepatitis C virus ( HCV ) infection . viii . Genetic immunodeficiency . 3 . Has receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior Day 1 ( Month 0 ) planning receive vaccine within 28 day Day 1 ( Month 0 ) . 4 . Has participate clinical trial another investigational product 30 day prior Day 1 ( Month 0 ) intent participate another clinical trial time conduct trial . 5 . Has previously participate clinical trial dengue candidate vaccine , previous receipt dengue vaccine . 6 . Is firstdegree relative individual involve trial conduct . 7 . For female childbearing potential sexually active , use acceptable contraceptive method least 2 month prior Day 1 ( Month 0 ) . 1 . Of childbearing potential defined status post onset menarche meeting follow condition : bilateral tubal ligation ( least 1 year previously ) , bilateral oophorectomy ( least 1 year previously ) hysterectomy . 2 . Acceptable birth control method define one following : i. Hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) . ii . Barrier ( condom spermicide diaphragm spermicide ) every time intercourse . iii . Intrauterine device ( IUD ) . iv . Monogamous relationship vasectomize partner ( partner must vasectomize least six month prior Day 1 [ Month 0 ] ) . 8 . Females childbearing potential sexually active , refuse use acceptable contraceptive method signing inform consent 6 week postvaccination .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>